Predicta Med Overview
Predicta Med is a platform that enables early detection and intervention selection of autoimmune diseases. Its platform gives healthcare providers an AI-powered method for shortening the diagnostic process of identifying autoimmune diseases and by that could enhance provider’s efficiency, improve treatment effectiveness and patient's care. A process which typically takes more than four years and at least four different doctors can be shortened significantly using the platform. Predicta Med’s deep learning engine aggregates EMR and claims data, and enriches and analyzes this data using state-of-the-art learning techniques. The platform discovers patients at risk of having an autoimmune disease and provides actionable insights to enable optimal intervention.
Cumulative Funding Raised Over Time ($)
$4.5MJan 2024
Latest News
Neutral
"A CEO has to be a doctor, politician, parent, and economic advisor" | CTech
Noam Schwartz, CEO of ActiveFence, and Shlomit Steinberg-Koch, CEO of Predicta Med, shared their experiences and insights on leadership and crisis management during a Growth+ project meeting organized by Calcalist and Poalim Tech. The discussion was part of a series of meetings aimed at providing advice and support to early-stage start-up companies. Schwartz and Steinberg-Koch discussed the challenges they faced in their respective companies and how they navigated through them. They also shared their thoughts on the changing role of the CEO in the face of various crises.
Management Changes
growth-positive
Meet the New Health-Tech Companies Joining the Cedars-Sinai Accelerator
The Cedars-Sinai Accelerator is welcoming 10 health-tech companies from around the world to its ninth accelerator class. The businesses are developing a variety of healthcare solutions, from monitoring devices for sepsis, heart failure, and stroke, to virtual reality video games aimed at helping children manage pain and anxiety during medical procedures. During the three-month program, company leaders get hands-on experience, along with mentorship from Cedars-Sinai researchers, administrators, and clinicians, to develop and refine the practical applications of their products and solutions. Each company will also receive a $100,000 investment from Cedars-Sinai.
InvestmentPartners
growth-positive
Predicta Med Raises Investment From CerraCap Ventures
Predicta Med, an autoimmune disease detection and intervention recommendation company, has received an investment from CerraCap Ventures. The amount of the deal was not disclosed. The investment will be used to accelerate growth and expand operations. Predicta Meds AI-based platform, PredictAI™, helps healthcare providers reduce immune-related disease diagnosis time. The company has partnerships with healthcare providers and has completed a program at Mayo Clinic Platform Accelerate. The article was published on February 13, 2023.
Investment
growth-positive
New technology speeds up diagnosis of 7 autoimmune diseases
Predicta Med, a medical technology startup, is using artificial intelligence and machine learning to help primary-care physicians diagnose autoimmune diseases. The company was founded in 2020 by Shlomit Steinberg-Koch, who was inspired by the death of her colleague and friend. Predicta Med has raised $2 million in funding so far and is about to close a full seed round. The company aggregates data from electronic medical records and insurance claims to provide decision support to physicians. It plans to launch its product by the end of 2022 and does not currently require FDA approval. Predicta Med aims to help family physicians detect autoimmune diseases earlier and prevent unnecessary pain and surgeries.
Investment
growth-positive
פרדיקטה מד היא היועץ שכל רופא משפחה צריך
Predicta Med, an Israeli startup, has developed an AI-based platform that can detect patients with autoimmune diseases and alert their family doctor. The system works by identifying disease characteristics based on accumulated medical knowledge and research, and then searching for patients whose medical records indicate these characteristics. The company has raised around $2 million so far and is about to close another funding round. It currently employs eight people and plans to expand gradually.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $5.5M |
| Last funding | $1M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 1 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.predicta-med.com/ |
| Careers | Careers page |
Locations
Tuval St 40, Ramat Gan, 5252247, Israel
Photos & Videos
1 item(s)
Predicta Med Business
Business models
B2B
Product stage
Beta
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceDeep LearningNatural Language ProcessingTags (13)
osteoarthritismultiple-sclerosisrecommendationsdiagnosticsceliac-diseaseemralgorithmsautoimmune-diseasesdecision-supportdigital-healthcaremedical-dataartificial-intelligenceearly-detectionPredicta Med Financials
$5.5M
Total funding
Undisclosed
Capital raised
$1M
Last funding
Seed
Funding stage
2
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$4.5MJan 2024
Private Equity Funding
Seed
Jan 2024
$4.5M
4T Ventures
Non-Equity Funding
GrantEvent
Jan 2024
$1M
Israel Innovation Authority
Predicta Med Lifecycle
Cumulative Funding Raised Over Time
$4.5MJan 2024
All Events
Seed
Jan 2024
$4.5M
4T Ventures
GrantEvent
Jan 2024
$1M
Israel Innovation Authority
Predicta Med News
5 articles
Neutral
"A CEO has to be a doctor, politician, parent, and economic advisor" | CTech
Noam Schwartz, CEO of ActiveFence, and Shlomit Steinberg-Koch, CEO of Predicta Med, shared their experiences and insights on leadership and crisis management during a Growth+ project meeting organized by Calcalist and Poalim Tech. The discussion was part of a series of meetings aimed at providing advice and support to early-stage start-up companies. Schwartz and Steinberg-Koch discussed the challenges they faced in their respective companies and how they navigated through them. They also shared their thoughts on the changing role of the CEO in the face of various crises.
Management Changes
growth-positive
Meet the New Health-Tech Companies Joining the Cedars-Sinai Accelerator
The Cedars-Sinai Accelerator is welcoming 10 health-tech companies from around the world to its ninth accelerator class. The businesses are developing a variety of healthcare solutions, from monitoring devices for sepsis, heart failure, and stroke, to virtual reality video games aimed at helping children manage pain and anxiety during medical procedures. During the three-month program, company leaders get hands-on experience, along with mentorship from Cedars-Sinai researchers, administrators, and clinicians, to develop and refine the practical applications of their products and solutions. Each company will also receive a $100,000 investment from Cedars-Sinai.
InvestmentPartners
growth-positive
Predicta Med Raises Investment From CerraCap Ventures
Predicta Med, an autoimmune disease detection and intervention recommendation company, has received an investment from CerraCap Ventures. The amount of the deal was not disclosed. The investment will be used to accelerate growth and expand operations. Predicta Meds AI-based platform, PredictAI™, helps healthcare providers reduce immune-related disease diagnosis time. The company has partnerships with healthcare providers and has completed a program at Mayo Clinic Platform Accelerate. The article was published on February 13, 2023.
Investment
growth-positive
New technology speeds up diagnosis of 7 autoimmune diseases
Predicta Med, a medical technology startup, is using artificial intelligence and machine learning to help primary-care physicians diagnose autoimmune diseases. The company was founded in 2020 by Shlomit Steinberg-Koch, who was inspired by the death of her colleague and friend. Predicta Med has raised $2 million in funding so far and is about to close a full seed round. The company aggregates data from electronic medical records and insurance claims to provide decision support to physicians. It plans to launch its product by the end of 2022 and does not currently require FDA approval. Predicta Med aims to help family physicians detect autoimmune diseases earlier and prevent unnecessary pain and surgeries.
Investment
growth-positive
פרדיקטה מד היא היועץ שכל רופא משפחה צריך
Predicta Med, an Israeli startup, has developed an AI-based platform that can detect patients with autoimmune diseases and alert their family doctor. The system works by identifying disease characteristics based on accumulated medical knowledge and research, and then searching for patients whose medical records indicate these characteristics. The company has raised around $2 million so far and is about to close another funding round. It currently employs eight people and plans to expand gradually.
InvestmentExpand
Predicta Med Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 20 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Predicta Med Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516150240 |
| Crunchbase | predicta-med |
| Phone | +972528467808 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-27T00:00:00.000Z |
| Created | 2019-10-08T00:00:00.000Z |
| Claimed | Yes |